Novelion Therapeutics Observes Rare Disease Day
February 28, 2019 07:00 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
February 06, 2019 02:30 ET
|
Novelion Therapeutics, Inc.
Out-licensing of commercialization rights allows for significant operating expense savingsUpfront payments improve near-term liquidity VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) --...
Novelion Therapeutics Announces Leadership Change
November 20, 2018 16:05 ET
|
Novelion Therapeutics, Inc.
Novelion General Counsel Benjamin Harshbarger Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics...
Novelion Therapeutics Reports Third Quarter 2018 Financial Results
November 09, 2018 08:46 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for...
Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
November 08, 2018 08:48 ET
|
Novelion Therapeutics, Inc.
- New Aegerion loan facility, provided by existing bondholders, strengthens balance sheet and is expected to provide bridge to a potential comprehensive long-term capital restructuring - Company...
Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
September 24, 2018 08:30 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...
Novelion Therapeutics Announces Next Phase of Operational Improvements
August 23, 2018 07:43 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
Novelion Therapeutics Reports Second Quarter 2018 Financial Results
August 07, 2018 08:30 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for...
Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
July 31, 2018 08:15 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to delivering new standards of care for people living...
Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
July 03, 2018 08:30 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, July 03, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) today announced that Mark Corrigan, M.D. has been appointed as Executive Chair of the Board of...